


## Pictilisib

Cat. No.:	HY-50094		
CAS No.:	957054-30-7		
Molecular Formula:	C <sub>23</sub> H <sub>27</sub> N <sub>7</sub> O <sub>3</sub> S <sub>2</sub>		
Molecular Weight:	513.64		
Target:	PI3K; Autophagy; Apoptosis		
Pathway:	PI3K/Akt/mTOR; Autophagy; Apoptosis		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 100 mg/mL (194.69 mM; ultrasonic and warming and heat to 60°C)

Concentration	Mass			
	1 mg	5 mg	10 mg	
1 mM	1.9469 mL	9.7344 mL	19.4689 mL	
5 mM	0.3894 mL	1.9469 mL	3.8938 mL	
10 mM	0.1947 mL	0.9734 mL	1.9469 mL	

Please refer to the solubility information to select the appropriate solvent.

#### In Vivo

- Add each solvent one by one: 0.5% MC >> 0.5% Tween-80  
Solubility: 5 mg/mL (9.73 mM); Suspended solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline  
Solubility: ≥ 2.5 mg/mL (4.87 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)  
Solubility: 2.5 mg/mL (4.87 mM); Suspended solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 90% corn oil  
Solubility: 2.5 mg/mL (4.87 mM); Suspended solution; Need ultrasonic

### BIOLOGICAL ACTIVITY

#### Description

Pictilisib (GDC-0941) is a potent inhibitor of PI3Kα/δ with an IC<sub>50</sub> of 3 nM, with modest selectivity against p110β (11-fold) and p110γ (25-fold).

#### IC<sub>50</sub> & Target

p110α 3 nM (IC <sub>50</sub> )	p110α-H1047R 3 nM (IC <sub>50</sub> )	p110α-E545K 3 nM (IC <sub>50</sub> )	p110δ 3 nM (IC <sub>50</sub> )
-----------------------------------	--	---	-----------------------------------

	p110 $\beta$ 33 nM (IC <sub>50</sub> )	p110 $\gamma$ 75 nM (IC <sub>50</sub> )	mTOR 0.58 $\mu$ M (Ki)	DNA-PK 1.23 $\mu$ M (IC <sub>50</sub> )
	Autophagy			
<b>In Vitro</b>	<p>Pictilisib (GDC-0941) and RP-56976 reduce tumor cell viability by 80% or greater in the breast cancer cell lines than single-agent treatment. GDC-0941 inhibits Akt phosphorylation and downstream targets of Akt signaling such as pPRAS40 and pS6 in Hs578T1.2 (PI3K<math>\alpha</math> wild-type), MCF7-neo/HER2 (PI3K<math>\alpha</math>-mutant), and MX-1 (PTEN-null) tumor models. Pictilisib (GDC-0941) decreases the time of RP-56976-induced mitotic arrest prior to apoptosis<sup>[1]</sup>. Pictilisib (GDC-0941) shows a high efficacy of antitumor activity in two ZD1839-resistant non-small cell lung cancer (NSCLC) cell lines, A549 and H460. Pictilisib (GDC-0941) is highly efficacious in combination with U0126 in inducing cell growth inhibition, G0-G1 arrest and cell apoptosis. H460 cells with activating mutations of PIK3CA are relatively more sensitive to Pictilisib (GDC-0941) than A549 cells with wild-type PIK3CA<sup>[3]</sup>. Pictilisib (GDC-0941) reduces PI3K pathway activity in both cell lines, illustrated by decreased pAK. Pictilisib (GDC-0941) significantly reduces secreted VEGF detected in the medium after hypoxic/anoxic exposure in all cells<sup>[4]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>			
<b>In Vivo</b>	<p>Pictilisib (GDC-0941) (150 mg/kg, p.o.) leads to tumor stasis in MCF7-neo/HER2-bearing animals model. Pictilisib (GDC-0941) and RP-56976 result in tumor regressions during the treatment period leading to enhanced antitumor responses<sup>[1]</sup>. Tumours in the Pictilisib (GDC-0941)-treated mice show a marked non-linear shrinkage, and when the Pictilisib (GDC-0941) treatment ceased, the tumours in the test cohort mice grow again<sup>[2]</sup>. Pictilisib (GDC-0941) (25 or 50 mg/kg) reduces tumor growth and PI3K and HIF-1 pathway activity in eGFP-FTC133 tumor-bearing mice<sup>[4]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>			

## PROTOCOL

### Cell Assay <sup>[1]</sup>

Cells are treated at EC<sub>50</sub> concentrations of Pictilisib (GDC-0941), RP-56976, or both for 4 or 24 hours and lysed in 1×Cell Extraction Buffer supplemented with protease inhibitors and Phosphatase Inhibitor Cocktails 1 and 2. Protein concentrations are determined using the Pierce BCA Protein Assay Kit. For immunoblots, equal amounts of protein are separated by electrophoresis through NuPAGE Bis-Tris 10% gradient gels, transferred onto polyvinylidene difluoride membranes using the Criterion system, and probed with monospecific primary antibodies. Specific antigen-antibody interactions are detected with IRDye 680 or IRDye 800 infrared secondary antibodies using a LI-COR imaging system.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### Animal Administration <sup>[1]</sup>

Female nu/nu mice are inoculated subcutaneously with MCF7-neo/HER2 or MX-1 breast cancer cells. When tumors reach a mean volume of 200 to 250 mm<sup>3</sup>, animals are size-matched and distributed into groups consisting of 10 animals per group. RP-56976 formulated in 3% EtOH, 97% saline is administered intravenously once weekly. Pictilisib (GDC-0941), formulated in MCT (0.5% methylcellulose, 0.2% Tween-80) is dosed orally and daily. MAXF1162 is an HER2+/ER+/PR+ patient-derived breast cancer tumor xenograft model established by directly implanting tumors subcutaneously from patient to NMRI nu/nu mice. Tumor volume is calculated. Tumor sizes are recorded twice weekly over the course of a study.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## CUSTOMER VALIDATION

- Nature. 2018 Aug;560(7719):499-503.
- Cell. 2023 Jun 22;186(13):2929-2949.e20.
- Cell Metab. 2021 Nov 2;33(11):2247-2259.e6.
- Cell Metab. 2012 Mar 7;15(3):382-94.
- Cancer Discov. 2012 May;2(5):425-33.

## REFERENCES

---

- [1]. Wallin JJ, et al. GDC-0941, a novel class I selective PI3K inhibitor, enhances the efficacy of RP-56976 in human breast cancer models by increasing cell death in vitro and in vivo. *Clin Cancer Res*. 2012 Jul 15;18(14):3901-11. Epub 2012 May 14.
- [2]. Wullschleger S, et al. Quantitative MRI establishes the efficacy of PI3K inhibitor (GDC-0941) multi-treatments in PTEN-deficient mice lymphoma. *Anticancer Res*. 2012 Feb;32(2):415-20.
- [3]. Zou ZQ, et al. The novel dual PI3K/mTOR inhibitor GDC-0941 synergizes with the MEK inhibitor U0126 in non-small cell lung cancer cells. *Mol Med Report*. 2012 Feb;5(2):503-8.
- [4]. Burrows N, et al. GDC-0941 inhibits metastatic characteristics of thyroid carcinomas by targeting both the phosphoinositide-3 kinase (PI3K) and hypoxia-inducible factor-1 $\alpha$  (HIF-1 $\alpha$ ) pathways. *J Clin Endocrinol Metab*. 2011 Dec;96(12):E1934-43. Epub 2011 Oct
- [5]. Folkes AJ, et al. The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of can
- [6]. Ni J, et al. Functional characterization of an isoform-selective inhibitor of PI3K-p110 $\beta$  as a potential anticancer agent. *Cancer Discov*. 2012 May;2(5):425-33.
- [7]. Cheng H, et al. A genetic mouse model of invasive endometrial cancer driven by concurrent loss of Pten and Lkb1 Is highly responsive to mTOR inhibition. *Cancer Res*. 2014 Jan 1;74(1):15-23.
- 

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA